Drug failure in diabetic kidney disease: translational barriers, target validation and trial de-risking strategies

More on GLP-1 and incretin signalling

• Semaglutide may protect kidneys by reducing vascular resistance

  Nature Medicine · 4 Oct 2026

  

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• Retatrutide reduces bodyweight in obesity and type 2 diabetes

  Lancet · 4 Oct 2026